Navigation Links
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
Date:4/14/2008

chief executive officer of Medivation. "The analysis of the association between PSA declines and clinical outcomes is ongoing. We look forward to providing additional results from this clinical trial at an upcoming medical conference."

The ongoing Phase 1-2 trial is an open-label U.S. study enrolling prostate cancer patients who have failed standard hormonal therapies. The study is currently planned to enroll patients in 4 dose-expansion cohorts. Of the 21 patients treated at the lowest expanded dose of 60 mg/day evaluated at three months, 43 percent showed a >50 percent decline in PSA levels from baseline. The study endpoints include safety, tolerability, pharmacokinetics, effects on serum PSA levels and disease progression.

Medivation expects to complete the study, and report final top-line results, in 2008. If these results are positive, Medivation expects to seek U.S. Food and Drug Administration (FDA) agreement to enter pivotal Phase 3 registration study in castration-resistant prostate cancer.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 2008, and approximately 28,660 men are expected to die this year from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

About Medivation

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and castration-resistant (also known as hormone-refractory) prostate cancer. The Company's strategy is to identify promising product candidates, to develop them in a rapid, cost-effective manner, and to seek development and/or commercialization partners a
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medivation Announces Senior Management Promotions
2. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
3. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
5. Boston Scientific Announces Japanese Approval of Heart Failure Lead
6. Vasogen Announces Implementation of Strategic Restructuring Plan
7. Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
8. EXL Announces Appointment of Rembert de Villa as Head of Transformation Services
9. Botaneco Announces Launch of Second Generation Oleosome Product
10. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
11. Signalife Announces Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... biosimilar therapeutics including high value and difficult to manufacture ... offering of 6,000,000 shares of its common stock at ... Of the shares being offered, 2,610,000 are being offered ... offered by existing stockholders. Pfenex will not receive any ...
(Date:4/24/2015)... 24, 2015  Navitas Life Sciences is delighted to announce ... Clinical and Regulatory Services. Shalabh is a proven leader in ... CEO of Kinapse, as well as a Strategy consultant at ... - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... "I am delighted to welcome Shalabh into this critical role ...
(Date:4/24/2015)... 2015 Seoul Semiconductor announced the ... applications in the lighting market. In recent ... this technology in emerging markets such as Russia, ... range of applications such as streetlight and area ... , First launched in 2005 the Acrich technology ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 Athena San ... development of executive women in San Diego’s technology and ... 17th Annual Pinnacle Awards at their Gala on April ... Hotel. Register now at http://athenasd.org/events/ , The ... the Athena San Diego vision of fostering networking, risk ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2
... 28, 2011 Nature,s Bioceuticals, a wholly owned subsidiary ... billion market chronic obstructive pulmonary disease market (COPD) with ... This all natural, non-synthetic, medicine was developed for the ... which are Emphysema and Chronic Bronchitis. We believe that ...
... at the Georgia Institute of Technology have developed a ... a key ingredient found in many explosives. ... on paper or paper-like material using standard inkjet technology, ... to the presence of explosives, such as improvised explosive ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a ... extracellular matrix for the diabetes, cancer, dermatology and ... to Halozyme,s clinical stage drug, pegylated rHuPH20 (PEGPH20). The ... on "Molecular Markers in Cancer", taking place October 27-29 ...
Cached Biology Technology:Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula 2Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula 3Low-cost paper-based wireless sensor could help detect explosive devices 2Low-cost paper-based wireless sensor could help detect explosive devices 3Low-cost paper-based wireless sensor could help detect explosive devices 4Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma 2Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma 3
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... , SAN FRANCISCO, CAFebruary 9, 2014Sometimes biology is cruel. ... code is the difference between health and a deadly ... studied disorders caused by these tiny changes, replicating them ... But now, scientists at the Gladstone Institutes have found ...
... regions associated with type 2 diabetes have been identified ... basis of the disease. DNA data was brought ... controls from four different ethnic groups. The research was ... countries on four continents, co-led by investigators from Oxford ...
... reaction usually is "Eww," but when they see a ... Why some animals use noxious scents while others ... is the question that biologists Tim Caro of the ... State University, Long Beach and sought to answer ...
Cached Biology News:Genome editing goes hi-fi 2Genome editing goes hi-fi 3Seven new genetic regions linked to type 2 diabetes 2Social or stinky? New study reveals how animal defenses evolve 2
... Top cover cold rolled steel with ... Work surface polyethylene ... glass 3 UV lamps ... lamp interlocked with fluorescent light ...
... Shaker provides the exact agitation needed ... very slow to fast speed and ... a gentle wave motion that lifts ... membranes to achieve faster, more uniform ...
The large Dodeca stainer shaking rack holds the staining trays in the large Dodeca stainer....
... VSR-50 Variable Speed Rocker, with 12" x 14" ... 12" x 14" table; 220V. The VSR-50 ... equipment for any lab. The VSR-50 provides a ... for a gentle to vigourous movement. This makes ...
Biology Products: